Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer: Final results from a phase II trial

ONCOLOGY

Volumn 15, Issue 2 SUPPL. 3, 2001, Pages 44-47

  Sánchez Rovira, Pedro ^c   Jaén, Ana ^c   González, Encarna ^c   Porras, Ignacio ^c   Dueñas, Rosario ^c   Medina, Begona ^c   Mohedano, Nicolás ^c   Fernández, Margarita ^c   Marios, Maximiliano ^c   Lozano, Ana ^a   Carrasco, Eva ^b  

^a Hosp Univ Ciudad de Jaén   (Spain)

^b ELI LILLY AND COMPANY   (Spain)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DOXORUBICIN; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HEART; HUMAN; METASTASIS; MIDDLE AGED; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; HEART; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PACLITAXEL; THROMBOCYTOPENIA;

EID: 0035257757     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
2. Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An Intergroup trial (abstract 2). Proc Am Soc Clin Oncol 16:1a, 1997.
3. Noble S, Goa KL: Gemcitabine: A review of its pharmacology and clinical potential in non-small-cell lung cancer and pancreatic cancer. Drugs 54:447-472, 1997.
4. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997.
5. Carmichael J, Possinger K, Philip P, et al: Gemcitabine: A phase II study in patients with advanced breast cancer (abstract 57). Proc Am Soc Clin Oncol 12:64, 1993.
6. Possinger K, Kaufmann M, Helsing M, et al: Advanced breast cancer: A phase II trial with gemcitabine (abstract 369). Eur J Cance 31 (suppl 5): 80, 1995.
7. Spielmann M, Pouillart P, Espie M, et al: Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline containing regimens (abstract 99). Ann Oncol 7(5):23, 1996.
8. Rothenberg ML, Sharma A, Weiss GR, et al: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 9:733-738, 1998.
9. Colomer R, Llombart A, Lluch A, et al: Biweekly paclitaxel and gemcitabine in advanced breast cancer. Phase II trial and predictive value of HER2 extracellular domain. P roc Am Soc Clin Oncol 19:373, 2000.
10. Pérez Manga G, Lluch A, Alba E, et al: Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial. J Clin Oncol 13:2545-2552, 2000.
11. Lozano A, Sánchez-Rovira P, Medina B, et al: Phase II biweekly paclitaxel, doxorubicin and gemcitabine as first-line chemotherapy for metastatic breast cancer: Preliminary results (abstract 84P). Ann Oncol 9 (suppl 4): 16, 1998.
12. Sánchez-Rovira P, Mohedano N, Moreno MA, et al: Preliminary results from a early phase II trial of combination gemcitabine and paclitaxel in metastatic breast cancer. Eur J Cancer 33 (suppl 8):S 154, 1997.
13. Dombernowsky P, Gehl J, Boesgard M, et al. Doxorubicin and paclitaxel: A highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23(suppl 11):23-27, 1996.
14. Cazap E, Ventriglia M, Rubio G, et al: Taxol plus doxorubicin in the treatment of metastatic breast cancer (abstract 248). Proc Am Soc Clin Oncol 15:146, 1996.
15. Gennari A, Donati S, Danesi R, et al: The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. Semin Oncol 27(suppl 2): 14-19, 2000.
16. Kroep JR, Tolis C, Voorn DA, et al: Paclitaxel and gemcitabine cell cycle interactions in non-small-cell lung cancer cell lines. Proc Am Assoc Cancer Res 40:678, 1999.
17. Amadori D, Frassineti GL, Zoli W, et al: A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin Oncol 23(suppl 11):23-27, 1996.
18. Amadori D, Frassineti G, Zoli W, et al: A phase I/II study of doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. Oncology 11(4 suppl 3):30-33, 1997.